ASH Medical Educators Institute: A View From the Classroom
Dr. Laura Michaelis interviews Drs. Molly Mandernach and Annie Im about their experience participating in the ASH Medical Educators Institute.
When Does Monoclonal Gammopathy Acquire Significance?
Drs. Bustoros, Liu, Sklavenitis-Pistofidis, and Ghobrial look at studies by Dr. Robert Kyle that have transformed the landscape of precursor conditions is plasma cell malig
Dr. Abdel-Wahab takes a look at studies that explore the enzyme METTL3 and RNA methyltransferases as a novel therapy for acute myeloid leukemia.
Dr. Abdel-Wahab reviews the FDA approval in 2017 of four new therapeutic options for treating acute myeloid leukemia patients.
Dr. Abdel-Wahab discusses the use of vitamin C to restore TET2 deficiency in combination with PARP inhibition in the treatment of leukemia.
Dr. Abdel-Wahab and Dr. Taylor look at a study that evaluates the safety of combining the anti-PD-L1 antibody atezolizumab with the novel hypomethylating agent guadecitabine in older adults with AML not eligible for standard induction therapy.
Dr. Abdel-Wahab provides an overview of histiocytoses or histiocytic neoplasms, some of the most challenging hematologic disorders to diagnose and categorize.
Dr. Abdel-Wahab discusses the effects of SAMHD1 depletion on the response to multiple chemotherapeutic agents.
Dr. Abdel-Wahab studies the role of the epitranscriptome in the context of normal and malignant hematopoiesis.
Dr. Abdel-Wahab and Dr. Taylor review the progress made during 2016 in understanding the molecular underpinnings of acute myeloid leukemia (AML) as well as in the use of precision medicine for patients with AML.
Dr. Abdel-Wahab and Dr. Taylor study the biology of mutant IDH1 in a myeloid-specific context with the additive effect of aging, and highlight one of the TET2-independent consequences of 2HG.
Dr. Abdel-Wahab and Dr. Taylor cover a study that measures the safety of combination ABT-199 and hypomethylating agents in older adults with acute myelogenous leukemia (AML), who are treatment-naive and not eligible for standard induction therapy.
January-February 2018Volume 15, Issue 1
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology